NASDAQ:VTGN VistaGen Therapeutics - VTGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.14 0.00 (-0.79%) (As of 03/29/2023 03:52 PM ET) Add Compare Share Share Today's Range$0.14▼$0.1550-Day Range$0.13▼$0.3052-Week Range$0.08▼$1.79Volume1.98 million shsAverage Volume6.34 million shsMarket Capitalization$30.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media VistaGen Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.15Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.26) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.09 out of 5 starsMedical Sector983rd out of 999 stocksPharmaceutical Preparations Industry482nd out of 489 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for VistaGen Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.91% of the outstanding shares of VistaGen Therapeutics have been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTGN. Previous Next 1.0 News and Social Media Coverage News SentimentVistaGen Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for VistaGen Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 14 people have searched for VTGN on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.01% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 27.29% of the stock of VistaGen Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for VistaGen Therapeutics are expected to grow in the coming year, from ($0.26) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About VistaGen Therapeutics (NASDAQ:VTGN) StockVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.Read More Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTGN Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comVistaGen Therapeutics, Inc. to Post FY2023 Earnings of ($0.26) Per Share, William Blair Forecasts (NASDAQ:VTGN)March 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)March 29, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 22, 2023 | seekingalpha.comVistagen up 17% after Phase 3 data for anxiety candidateMarch 22, 2023 | finance.yahoo.comVistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety DisorderMarch 9, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)March 8, 2023 | finance.yahoo.comVistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive DisorderMarch 2, 2023 | finance.yahoo.comVistagen to Present at Cowen 43rd Annual Health Care ConferenceMarch 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 1, 2023 | finance.yahoo.comVistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of MigraineFebruary 9, 2023 | msn.comVistaGen Therapeutics's Return On Capital Employed InsightsFebruary 8, 2023 | finance.yahoo.comVistaGen Shares Plunge Amid Uncertainty Around Its Anxiety TrialFebruary 7, 2023 | markets.businessinsider.comHere's what Wall Street expects from VistaGen Therapeutics's earningsFebruary 6, 2023 | msn.comPreview: VistaGen Therapeutics's EarningsFebruary 6, 2023 | finance.yahoo.comVistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023February 2, 2023 | finance.yahoo.comVistagen Announces Closing of Pherin Pharmaceuticals AcquisitionJanuary 26, 2023 | benzinga.comInvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical TrialJanuary 25, 2023 | seekingalpha.comVTGN VistaGen Therapeutics, Inc.January 24, 2023 | finance.yahoo.comVistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive DisorderJanuary 10, 2023 | finance.yahoo.comVistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with AnxietyJanuary 5, 2023 | benzinga.comVistaGen Therapeutics Stock (NASDAQ:VTGN), Quotes and News SummaryDecember 22, 2022 | msn.comVistaGen Therapeutics Earnings Perspective: Return On Capital EmployedDecember 21, 2022 | finance.yahoo.comVistagen to Acquire Pherin PharmaceuticalsDecember 21, 2022 | finance.yahoo.comVistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma AcquisitionDecember 6, 2022 | marketwatch.comVistagen Therapeutics Shares Rise on FDA Fast-Track Designation >VTGNDecember 6, 2022 | finance.yahoo.comVistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive DisorderNovember 30, 2022 | finance.yahoo.comVistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive DisorderSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTGN Company Calendar Last Earnings2/07/2023Today3/29/2023Fiscal Year End3/31/2023Next Earnings (Estimated)6/22/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTGN CUSIPN/A CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,760,000.00 Net Margins-5,614.37% Pretax Margin-5,613.99% Return on Equity-158.24% Return on Assets-125.05% Debt Debt-to-Equity RatioN/A Current Ratio6.08 Quick Ratio6.08 Sales & Book Value Annual Sales$1.11 million Price / Sales27.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book0.45Miscellaneous Outstanding Shares219,330,000Free Float210,531,000Market Cap$30.53 million OptionableNot Optionable Beta1.09 Key ExecutivesShawn K. SinghChief Executive Officer & DirectorJerrold D. DotsonChief Financial Officer, Secretary & VPEllis WilsonVice President-Global Clinical OperationsJessica R. HaskellVice President & Associate General CounselAnn CunninghamDirector & Chief Commercial OfficerKey CompetitorsOrgenesisNASDAQ:ORGSEledon PharmaceuticalsNASDAQ:ELDNPalatin TechnologiesNYSE:PTNYumanity TherapeuticsNASDAQ:YMTXMEI PharmaNASDAQ:MEIPView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 137,200 shares on 2/16/2023Ownership: 0.144%Morgan StanleyBought 94,507 shares on 2/15/2023Ownership: 0.114%Belvedere Trading LLCBought 5,100 shares on 2/15/2023Ownership: 0.000%Two Sigma Investments LPSold 185,121 shares on 2/14/2023Ownership: 0.301%Geode Capital Management LLCSold 107,075 shares on 2/13/2023Ownership: 1.492%View All Insider TransactionsView All Institutional Transactions VTGN Stock - Frequently Asked Questions Should I buy or sell VistaGen Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares. View VTGN analyst ratings or view top-rated stocks. How have VTGN shares performed in 2023? VistaGen Therapeutics' stock was trading at $0.1030 at the beginning of 2023. Since then, VTGN shares have increased by 34.1% and is now trading at $0.1381. View the best growth stocks for 2023 here. When is VistaGen Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 22nd 2023. View our VTGN earnings forecast. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Tuesday, February, 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The firm earned $0.18 million during the quarter, compared to analysts' expectations of $0.31 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 158.24% and a negative net margin of 5,614.37%. What ETF holds VistaGen Therapeutics' stock ? Psyk Etf holds 77,466 shares of VTGN stock, representing 0.60% of its portfolio. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP). What is VistaGen Therapeutics' stock symbol? VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN." Who are VistaGen Therapeutics' major shareholders? VistaGen Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (2.32%), Geode Capital Management LLC (1.49%), Two Sigma Investments LP (0.30%), MAI Capital Management (0.30%), Alliancebernstein L.P. (0.14%) and GPS Wealth Strategies Group LLC (0.12%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par. View institutional ownership trends. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VistaGen Therapeutics' stock price today? One share of VTGN stock can currently be purchased for approximately $0.14. How much money does VistaGen Therapeutics make? VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $30.29 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. How can I contact VistaGen Therapeutics? VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602. This page (NASDAQ:VTGN) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.